Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

A Phase 2a, Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center Study To Assess The Efficacy And Safety Profile Of Pf-06651600 In Subjects With Moderate To Severe Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate

This is an 8 week study to assess the efficacy and safety profile of PF-06651600 in seropositive subjects with rheumatoid arthritis with an inadequate response to methotrexate (up to approximately 50% of subjects may also have had an inadequate response to 1 anti-TNF biologic).

Inclusion Criteria

• Subjects between the ages of 18 and 75 years, inclusive
• Must have moderate-to-severe, active Rheumatoid Arthritis
• Must have had an inadequate response to Methotrexate
• Subjects may have received one approved TNF inhibiting biologic agent that was inadequately effective and/or not tolerated

Exclusion Criteria

• Subjects with any acute or chronic infections or infection history
• Have acute or active chronic dermatological disorders prior to study start
• Any major illness/condition(s) or evidence of an unstable clinical condition that in the judgment of the investigator would make the subject inappropriate for entry into this study
• Known immunodeficiency disorder or a first degree relative with hereditary immunodeficiency
• Any live (attenuated) vaccines or current routine household contact with anyone who has received live (attenuated) vaccine